Stockscreener 앱 받기
1.67
4.02%
-0.07
시간 외 거래:
1.70
0.03
+1.80%
전일 마감가:
$1.74
열려 있는:
$1.82
하루 거래량:
3.95M
Relative Volume:
1.30
시가총액:
$118.75M
수익:
$391.70K
순이익/손실:
$-52.34M
주가수익비율:
-2.2267
EPS:
-0.75
순현금흐름:
$-45.92M
1주 성능:
-9.24%
1개월 성능:
+33.60%
6개월 성능:
+554.90%
1년 성능:
+53.21%
1일 변동 폭
$1.65
$1.84
1주일 범위
$1.57
$1.89
52주 변동 폭
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
OVID을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.67 | 123.73M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-08 | 재개 | B. Riley Securities | Buy |
| 2024-06-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 개시 | B. Riley Securities | Buy |
| 2024-04-29 | 개시 | H.C. Wainwright | Buy |
| 2024-04-05 | 개시 | Wedbush | Outperform |
| 2023-12-21 | 개시 | BTIG Research | Buy |
| 2023-10-13 | 개시 | Oppenheimer | Outperform |
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Combining machine learning predictions for Ovid Therapeutics Inc.July 2025 Summary & Daily Technical Forecast Reports - newser.com
Is a relief rally coming for Ovid Therapeutics Inc. holdersWeekly Trade Recap & Fast Entry Momentum Trade Alerts - newser.com
Is Ovid Therapeutics Inc. (1OT) stock protected from inflationMarket Performance Summary & Verified Technical Signals - newser.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Yahoo Finance
Oppenheimer Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
Ovid Therapeutics' (OVID) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Will Ovid Therapeutics Inc. benefit from macro trendsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Real time pattern detection on Ovid Therapeutics Inc. stock2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Ovid Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Exceptional Trading Strategies - earlytimes.in
Market reaction to Ovid Therapeutics Inc.’s recent newsRate Hike & Breakout Confirmation Alerts - newser.com
Ovid spikes as Wedbush moves to Outperform on lead asset - MSN
Ovid Therapeutics (OVID) Surges on Positive Analyst Rating - GuruFocus
Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says - MarketScreener
Technical signs of recovery in Ovid Therapeutics Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com
What data driven models say about Ovid Therapeutics Inc.’s futureWeekly Risk Report & High Yield Equity Trading Tips - newser.com
What drives PSP Swiss Property AG Common Stock P7S0 stock priceCapital Gains Strategies & Follow Top Performers in the Community - earlytimes.in
Is Ovid Therapeutics Inc. (1OT) stock vulnerable to rate hikesJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Ovid Therapeutics Inc. with AITrade Volume Report & Real-Time Buy Zone Alerts - newser.com
Tools to assess Ovid Therapeutics Inc.’s risk profileEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Hudson Yards seizure drug company raises $81M after cutting expenses - Crain's New York Business
What analysts say about Ovid Therapeutics Inc 1OT stockStock Rotation Strategies & Minimal Capital Investment - earlytimes.in
Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing - Sahm
Ovid Therapeutics Inc. (OVID) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know - Yahoo Finance
Wedbush Adjusts Price Target on Ovid Therapeutics to $5 From $3, Maintains Outperform Rating - MarketScreener
What’s next for Ovid Therapeutics Inc. stock priceJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Ovid Therapeutics Sets Market Trends with Successful Trials - Kalkine Media
Ovid Therapeutics Inc. announced that it has received $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC - MarketScreener
Forecasting Ovid Therapeutics Inc. price range with options data2025 Technical Overview & Daily Stock Trend Watchlist - newser.com
Why Ovid Therapeutics Inc. stock is popular among millennialsJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com
Ovid Therapeutics rises on $175 million placing and research update - The Pharma Letter
Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results - Yahoo Finance
Ovid announces positive topline results for the - GlobeNewswire
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Raises Target Price to $5 - 富途牛牛
Ovid Therapeutics Secures $175.1M in Private Placement - TipRanks
Ovid Therapeutics Inc. announced that it expects to receive $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC - MarketScreener
Ovid Therapeutics Stock: Analyzing Market Movement - timothysykes.com
Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders - Seeking Alpha
OVID Stock Surge: Opportunity or Risk? - StocksToTrade
Ovid Therapeutics Inc. (OVID) Stock: Rallies as Major Investors Join $175M Private Placement - parameter.io
Ovid Therapeutics Inc. (OVID) Stock: Soars on $81M Initial Funding, PIPE Could Reach $175M - CoinCentral
Wedbush Adjusts Ovid Therapeutics Price Target to $5 From $3, Maintains Outperform Rating - MarketScreener
Ovid Therapeutics (OVID) Surges After Positive Study Results - GuruFocus
Transcript : Ovid Therapeutics Inc.Special Call - MarketScreener
Ovid Therapeutics Surges: Is It a Buy? - StocksToTrade
Ovid Therapeutics Rockets 19% on Game-Changing Epilepsy Drug Breakthrough – Why This Could Shake Up Brain Health Investing - RagingBull
Ovid rises after positive results from epilepsy study (OVID) - Seeking Alpha
Ovid Therapeutics Surge: Market Moves and Metrics - timothysykes.com
Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why - Stocktwits
Ovid Therapeutics Raises $175 Million Through PIPE Financing - Finimize
Ovid Therapeutics (OVID) Secures $175M in PIPE Financing Deal - GuruFocus
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ovid Therapeutics Inc 주식 (OVID) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
5.74%
자본화:
|
볼륨(24시간):